At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers
In Brief
A Phase 2 clinical trial evaluating Povidone-Iodine 2%, Povidone-Iodine 0.5%, and 1 other intervention for COVID-19. Completed, enrolled 47 participants across 1 site.
Detailed Summary
The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients. The primary outcome measure is SARS-CoV-2 viral titers in the nasal cavity and nasopharynx. In vitro studies have shown PVP-I to be highly virucidal against the viruses which cause SARS and MERS. Additionally, clinical studies have shown PVP-I saline sprays to be well tolerated in human subjects. PVP-I oral rinses and sprays have been trialed as methods to reduce the incidence and symptoms of viruses which cause the "common cold."
Study Details
Timeline
Interventions
Two sprays to each nare of PVP-I 2% via nasal spray bottle, four times a day
Two sprays to each nare of PVP-I 0.5% via nasal spray bottle, four times a day
Two sprays to each nare of isotonic saline (0.9% NaCl) via nasal spray bottle, four times a day